Answers are grounded in this paper and cite their sources.
Clinical review demonstrates reduced cardiovascular death and coronary events in high-risk patients, highlighting the value of targeted vaccination.
Cardiovascular disease is a leading cause of morbidity and mortality. Individuals with underlying cardiovascular disease are at high risk for adverse outcomes from influenza infections. Although additional studies are needed, current evidence suggests the influenza vaccine may reduce the risk of cardiovascular death and coronary events. In addition to their overall efforts to encourage influenza vaccination for all eligible persons, pharmacists should pay special attention to these high-risk individuals.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: